Skip to main content

Advertisement

Fig. 1 | BMC Medicine

Fig. 1

From: Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial

Fig. 1

Clinical trial profile. a Study Phase where the presence of asexual parasites (1,000 - 200,000 parasites/μL) at screening was an inclusion criterion (initial 143 and final 67 participants). b Study Phase where children with patent gametocytes, regardless of their asexual parasite count, at screening were eligible (150 participants). Participants were considered to have a complete follow-up, if they had a total of seven follow-up visits (days 0, 1, 2, 3, 7, 10, 14). AL artemether-lumefantrine, PQ primaquine

Back to article page